Date: 2016-04-20
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Immune Design (USA - MA)
Product: G100 and ZVex™ platform
Action
mechanism:
- immunotherapy product. G100 is a product candidate generated from the company's GLAAS™ discovery platform, and includes a specific formulation of Glucopyranosyl Lipid A (GLA), a synthetic, toll-like receptor-4 (TLR-4) agonist. G100 is part of Immune Design's intratumoral immune activation, or 'Endogenous Antigen,' approach to treating cancer, which leverages the activation of dendritic and other immune cells in the tumor microenvironment to potentially create a robust immune response against the tumor's preexisting diverse set of antigens. Preclinical and clinical data have demonstrated the ability of G100 to activate dendritic cells in tumors and to increase antigen-dependent systemic humoral and cellular Th1 immune responses.
Disease: non-Hodgkin lymphoma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 20, 2016, Immune Design announced the presentation of data highlighting the ability of its G100 product candidate, comprised of GLA in a stable emulsion, to modulate the tumor microenvironment and trigger local and systemic immune responses following its direct injection in a murine lymphoma model. G100 induced broad pro-inflammatory cytokine and chemokine responses, while also upregulating activating genes in immune cells, leading to the switch from a "cold" to a "hot" tumor state. In addition, the upregulation of checkpoints such as PD-L1 in the G100-treated tumors suggests potential synergy with immune checkpoint inhibitors. These data support IMDZ's ongoing trial of G100 in follicular non-Hodgkin lymphoma in combination with local radiation therapy and Keytruda® (pembrolizumab). This phase 1b/2 study is evaluating intratumoral G100 in patients with follicular non-Hodgkin's lymphoma and is currently enrolling patients (NCT02501473). The study is evaluating the intratumoral administration of G100 with intravenous administration of Keytruda® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with follicular non-Hodgkin's lymphoma receiving local radiation, pursuant to a collaboration with Merck. The study is designed to evaluate G100 plus local radiation and Keytruda® compared to G100 plus local radiation alone. In addition to an evaluation of the safety of the combination, the study will assess the response in both injected and non-injected lesions.
- Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. The presentation was titled "Intratumoral Injection of G100 (TLR4 agonist Glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity" (Abstract #4885).
Is
general: Yes
